Bionova foresees 300 per cent growth by end of FY 2017

By: |
Updated: October 29, 2014 1:09 PM

Will be launching series of human wellness based OTC products

Will be launching series of human wellness based OTC products

Bangalore-based application research and formulation company, Bionova is betting on the rapid development of Indian biopharma industry and foresee a 300 per cent revenue growth by end of financial year 2017. The company is planning to launch a range of OTC products (Over-the-counter non-prescription) for infant nutrition, child growth, diabetic supplements and wellness. The new range of product line will enable Bionova to develop a competitive stand along the line of present Indian and global players in the market.
Suddhir Jain, Managing Director, Bionova said, “We are poised to achieve a strong set of numbers during the current financial year. The new organisational structure will enable us to deliver superior results while our current product range has been performing strongly. Our human wellness focused unique formulations vertical is growing at a rapid pace and will be launching a range of product line over the next few months. We are accelerating research and invention initiatives to establish the company as globally respected premium pharmaceutical brand, while the company is remained focused on developing its pipeline products across its business segments to sustain our long-term growth.”

EH News BureauMumbai

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.